CN106061974B - 作为wnt途径的调节剂的顺丁烯二酰亚胺衍生物 - Google Patents
作为wnt途径的调节剂的顺丁烯二酰亚胺衍生物 Download PDFInfo
- Publication number
- CN106061974B CN106061974B CN201480075684.XA CN201480075684A CN106061974B CN 106061974 B CN106061974 B CN 106061974B CN 201480075684 A CN201480075684 A CN 201480075684A CN 106061974 B CN106061974 B CN 106061974B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- nmr
- 400mhz
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **N(*)C(C(N(C(C(N1*)=O)=C(*)C1=O)[U]CC=*)[Re])=O Chemical compound **N(*)C(C(N(C(C(N1*)=O)=C(*)C1=O)[U]CC=*)[Re])=O 0.000 description 3
- BGRZZOOMIVIDPE-UHFFFAOYSA-N CC(C(N1C)=C)=C(CCCNCC(Nc2ccc(-c3ccccc3)c(F)c2)=O)C1=O Chemical compound CC(C(N1C)=C)=C(CCCNCC(Nc2ccc(-c3ccccc3)c(F)c2)=O)C1=O BGRZZOOMIVIDPE-UHFFFAOYSA-N 0.000 description 1
- KPGRLIZBHYVATJ-UHFFFAOYSA-N CN(C(C1=C2N(CC(Nc(cc3)ccc3-c3cnccc3)=O)CCC1)=O)C2=O Chemical compound CN(C(C1=C2N(CC(Nc(cc3)ccc3-c3cnccc3)=O)CCC1)=O)C2=O KPGRLIZBHYVATJ-UHFFFAOYSA-N 0.000 description 1
- QRNKUWVJNOSYTK-UHFFFAOYSA-N CN(C(C1=C2N(CC(Nc(ccc(-c3ccccc3)c3)c3OC)=O)CCC1)=O)C2=O Chemical compound CN(C(C1=C2N(CC(Nc(ccc(-c3ccccc3)c3)c3OC)=O)CCC1)=O)C2=O QRNKUWVJNOSYTK-UHFFFAOYSA-N 0.000 description 1
- ZEZYRWPOFIOGCX-UHFFFAOYSA-N Cc1cc(-c(cc2)nnc2NC(CN(CCC2)C(C(N3C4CC4)=O)=C2C3=O)=O)cnc1 Chemical compound Cc1cc(-c(cc2)nnc2NC(CN(CCC2)C(C(N3C4CC4)=O)=C2C3=O)=O)cnc1 ZEZYRWPOFIOGCX-UHFFFAOYSA-N 0.000 description 1
- SMFUDWBYZYSYHN-UHFFFAOYSA-N Cc1nc(-c(cc2)cnc2N)c[s]1 Chemical compound Cc1nc(-c(cc2)cnc2N)c[s]1 SMFUDWBYZYSYHN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322334.2 | 2013-12-17 | ||
| GBGB1322334.2A GB201322334D0 (en) | 2013-12-17 | 2013-12-17 | Maleimide derivatives as modulators of WNT pathway |
| PCT/SG2014/000601 WO2015094118A1 (en) | 2013-12-17 | 2014-12-17 | Maleimide derivatives as modulators of wnt pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106061974A CN106061974A (zh) | 2016-10-26 |
| CN106061974B true CN106061974B (zh) | 2018-04-20 |
Family
ID=50031067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480075684.XA Expired - Fee Related CN106061974B (zh) | 2013-12-17 | 2014-12-17 | 作为wnt途径的调节剂的顺丁烯二酰亚胺衍生物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9981964B2 (enExample) |
| EP (1) | EP3083622B1 (enExample) |
| JP (1) | JP6511450B2 (enExample) |
| KR (1) | KR20160104010A (enExample) |
| CN (1) | CN106061974B (enExample) |
| AU (1) | AU2014367283B2 (enExample) |
| BR (1) | BR112016013618A8 (enExample) |
| CA (1) | CA2933682A1 (enExample) |
| ES (1) | ES2674096T3 (enExample) |
| GB (1) | GB201322334D0 (enExample) |
| SG (1) | SG11201604848UA (enExample) |
| WO (1) | WO2015094118A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322334D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | Maleimide derivatives as modulators of WNT pathway |
| GB201409783D0 (en) * | 2014-06-02 | 2014-07-16 | Agency Science Tech & Res | Phthalimide derivatives as modulators of WNT pathway |
| GB201604970D0 (en) * | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| CN109867661B (zh) * | 2017-12-05 | 2022-07-19 | 中国医学科学院药物研究所 | 调节wnt信号通路的酰胺类化合物及其用途 |
| KR20200118005A (ko) * | 2018-02-05 | 2020-10-14 | 위니베르시떼 드 스트라스부르 | 통증 치료용 화합물 및 조성물 |
| RS63124B1 (sr) | 2018-03-08 | 2022-05-31 | Incyte Corp | Aminopirazin diol jedinjenja kao pi3k-y inhibitori |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN110317204B (zh) * | 2019-08-02 | 2022-02-08 | 安徽农业大学 | 吡唑并嘧啶酮类衍生物及其制备方法和应用 |
| PE20221445A1 (es) | 2019-10-16 | 2022-09-21 | Chemocentryx Inc | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| CN120737090B (zh) * | 2025-08-15 | 2025-11-21 | 广州医科大学附属市八医院 | 一种化合物或组合物及其在制备具有抗癌作用的药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1027165C (zh) * | 1988-07-15 | 1994-12-28 | 拜尔公司 | 7-环取代-3-喹诺酮羧酸衍生物的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798619A (en) | 1980-06-02 | 1989-01-17 | American Cyanamid Co. | 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents |
| US6444617B1 (en) | 1998-07-28 | 2002-09-03 | Nihon Nohyaku Co., Ltd. | Fused-heterocycle dicarboxylic acid diamide derivatives or salts thereof, herbicide and usage thereof |
| KR101288753B1 (ko) | 2002-12-03 | 2013-07-23 | 바이엘 에스.에이.에스 | 살충성 5-(아실아미노)피라졸 유도체 |
| JP5116660B2 (ja) | 2005-03-31 | 2013-01-09 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｈｉｖインテグラーゼ阻害剤 |
| TW200904817A (en) | 2007-06-19 | 2009-02-01 | Astrazeneca Ab | Compounds and uses thereof |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| FR2927331B1 (fr) * | 2008-02-07 | 2011-05-20 | Centre Nat Rech Scient | Nouveaux derives anti-infectieux, leur procede de preparation, compositions pharmaceutiques les contenant et leurs utilisations en therapeutique. |
| US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| WO2010075282A1 (en) * | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
| EP2423211B1 (en) | 2009-04-20 | 2014-04-16 | Kaneka Corporation | Processes for producing (1s,6s)- or (1r,6r)-cis-2,8-diazabicyclo[4.3.0]nonane and intermediate thereof |
| US8865704B2 (en) * | 2009-10-07 | 2014-10-21 | Siena Biotech S.P.A. | Wnt pathway antagonists |
| US9174988B2 (en) | 2009-10-27 | 2015-11-03 | Trustees Of Boston University | Small molecule inhibitors of hepatitis C virus |
| WO2012136492A1 (en) * | 2011-04-04 | 2012-10-11 | Siena Biotech S.P.A. | Wnt pathway antagonists |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| GB201322334D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | Maleimide derivatives as modulators of WNT pathway |
| GB201409783D0 (en) * | 2014-06-02 | 2014-07-16 | Agency Science Tech & Res | Phthalimide derivatives as modulators of WNT pathway |
-
2013
- 2013-12-17 GB GBGB1322334.2A patent/GB201322334D0/en not_active Ceased
-
2014
- 2014-12-17 US US15/105,312 patent/US9981964B2/en active Active
- 2014-12-17 AU AU2014367283A patent/AU2014367283B2/en not_active Ceased
- 2014-12-17 CN CN201480075684.XA patent/CN106061974B/zh not_active Expired - Fee Related
- 2014-12-17 ES ES14871224.3T patent/ES2674096T3/es active Active
- 2014-12-17 JP JP2016540530A patent/JP6511450B2/ja not_active Expired - Fee Related
- 2014-12-17 EP EP14871224.3A patent/EP3083622B1/en not_active Not-in-force
- 2014-12-17 KR KR1020167019111A patent/KR20160104010A/ko not_active Ceased
- 2014-12-17 SG SG11201604848UA patent/SG11201604848UA/en unknown
- 2014-12-17 BR BR112016013618A patent/BR112016013618A8/pt not_active IP Right Cessation
- 2014-12-17 WO PCT/SG2014/000601 patent/WO2015094118A1/en not_active Ceased
- 2014-12-17 CA CA2933682A patent/CA2933682A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1027165C (zh) * | 1988-07-15 | 1994-12-28 | 拜尔公司 | 7-环取代-3-喹诺酮羧酸衍生物的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2933682A1 (en) | 2015-06-25 |
| JP6511450B2 (ja) | 2019-05-15 |
| EP3083622B1 (en) | 2018-03-21 |
| GB201322334D0 (en) | 2014-01-29 |
| SG11201604848UA (en) | 2016-07-28 |
| US9981964B2 (en) | 2018-05-29 |
| BR112016013618A8 (pt) | 2020-05-19 |
| EP3083622A4 (en) | 2017-05-10 |
| KR20160104010A (ko) | 2016-09-02 |
| US20160318926A1 (en) | 2016-11-03 |
| CN106061974A (zh) | 2016-10-26 |
| AU2014367283A1 (en) | 2016-06-23 |
| WO2015094118A1 (en) | 2015-06-25 |
| ES2674096T3 (es) | 2018-06-27 |
| EP3083622A1 (en) | 2016-10-26 |
| JP2016540802A (ja) | 2016-12-28 |
| AU2014367283B2 (en) | 2018-05-24 |
| BR112016013618A2 (enExample) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106061974B (zh) | 作为wnt途径的调节剂的顺丁烯二酰亚胺衍生物 | |
| US11434245B2 (en) | WNT pathway modulators | |
| TWI536991B (zh) | 黏著斑激酶之抑制劑 | |
| KR102241111B1 (ko) | Ｍｅｋ 억제제로서 헤테로사이클릴 화합물 | |
| US20250376473A1 (en) | Prmts inhibitor and use thereof | |
| CN107922386B (zh) | 1,4-二取代的咪唑衍生物 | |
| KR20160132470A (ko) | 피페리딘-다이온 유도체 | |
| TW201249823A (en) | Tetrasubstituted cyclohexyl compounds as kinase inhibitors | |
| WO2019101086A1 (zh) | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 | |
| WO2009131173A1 (ja) | 2-アミノキナゾリン誘導体 | |
| CN114008025A (zh) | Acss2抑制剂和其使用方法 | |
| WO2015187094A1 (en) | Phthalimide derivatives as modulators of wnt pathway | |
| WO2010001990A1 (ja) | 四環系化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180420 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |